Поисковые предложения

1. ("Protein Binding"[Mesh] AND "Contrast Media"[Mesh]) AND "Magnetic Resonance Imaging"[Mesh]

2. ("Protein Binding"[Mesh] AND "Magnetic Resonance Imaging"[Mesh]) AND ("Contrast Media/blood"[Mesh] OR "Contrast Media/chemistry"[Mesh] OR "Contrast Media/diagnostic use"[Mesh] OR "Contrast Media/pharmacokinetics"[Mesh] OR "Contrast Media/pharmacology"[Mesh])

3. Bellin[au] AND contrast*[ti] AND 2003[dp]

4. "J Magn Reson Imaging"[Journal] AND Ruehm[au] AND 2001[dp]

В PubChem для поиска структуры гадоксетовой кислоты («Примовист») поисковое предложение формулировалось следующим образом: gadoxetic[All Fields] AND acid[All Fields].

Список использованной литературы

1. 1. Панов В. О., Шимановский Н. Л., Степанянц А. У., Сергеев П. В.: Критерий оценки взаимодействия лигандов с макромолекулами по данным ЯМР спектроскопии высокого разрешения. // Биофизика 1988, 33:776-780

2. 2. Сергеев П. В., Свиридов Н. К., Шимановский Н. Л.: Контрастные средства. // Медицина 1993

3. 3. Сергеев П. В., Шимановский Н. Л., Панов В. О.: Магнитно-резонансные контрастные средства. // Хим-фарм журн 1989, 1:30-33

4. 4. Cavagna F. M., Maggioni F., Castelli P. M., Dapra M., Imperatori L. G., Lorusso V., Jenkins B. G.: Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. // Invest Radiol 1997, 32 (12):780-796

5. 5. Claussen C., Laniado M., Schorner W., Niendorf H. P., Weinmann H. J., Fiegler W., Felix R.: Gadolinium-DTPA in MR imaging of glioblastomas and intracranial metastases. // AJNR American journal of neuroradiology 1985, 6 (5):669-674

6. 6. Hamm B., Thoeni R. F., Gould R. G., Bernardino M. E., Luning M., Saini S., Mahfouz A. E., Taupitz M., Wolf K. J.: Focal liver lesions: characterization with nonenhanced and dynamic contrast material-enhanced MR imaging. // Radiology 1994, 190 (2):417-423

7. 7. Marchal G., Zhang X., Ni Y., Van Hecke P., Yu J., Baert A. L.: Comparison between Gd-DTPA, Gd-EOB-DTPA, and Mn-DPDP in induced HCC in rats: a correlation study of MR imaging, microangiography, and histology. // Magnetic resonance imaging 1993, 11 (5):665-674

8. 8. Bellin M. F., Webb J. A., Van Der Molen A. J., Thomsen H. S., Morcos S. K.: Safety of MR liver specific contrast media. // European radiology 2005, 15 (8):1607-1614

9. 9. Lauffer R. B., Parmelee D. J., Dunham S. U., Ouellet H. S., Dolan R. P., Witte S., McMurry T. J., Walovitch R. C.: MS-325: albumin-targeted contrast agent for MR angiography. // Radiology 1998, 207 (2):529-538

10. 10. Rasanen H. T., Manninen H. I., Vanninen R. L., Vainio P., Berg M., Saari T.: Mild carotid artery atherosclerosis: assessment by 3-dimensional time-of-flight magnetic resonance angiography, with reference to intravascular ultrasound imaging and contrast angiography. // Stroke; a journal of cerebral circulation 1999, 30 (4):827-833

11. 11. Поляев Ю. А., Юдин А. Л., Шимановский Н. Л.: Применение контрастных средств в лучевой диагностике. Москва: Изд-во "Калганов"; 2010, 241-310,387-408

12. 12. Ринкк А. Р.: Магнитный резонанс в медицине, 3 edn. Москва: Изд.-кий дом "Гэотар-мед"; 2003, 147-162

13. 13. MacFall J. R., Wehrli F. W., Breger R. K., Johnson G. A.: Methodology for the measurement and analysis of relaxation times in proton imaging. // Magnetic resonance imaging 1987, 5 (3):209-220

14. 14. Мартиросов Э. Г., Николаев Д. В., Руднев С. Г.: Технологии и методы определения состава тела человека. Москва: "Наука"; 2006, 156-159

15. 15. Hamm B., Staks T., Muhler A., Bollow M., Taupitz M., Frenzel T., Wolf K. J., Weinmann H. J., Lange L.: Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. // Radiology 1995, 195 (3):785-792

16. 16. Caravan P., Cloutier N. J., Greenfield M. T., McDermid S. A., Dunham S. U., Bulte J. W., Amedio J. C., Jr., Looby R. J., Supkowski R. M., Horrocks W. D., Jr. et al: The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. // Journal of the American Chemical Society 2002, 124 (12):3152-3162

17. 17. Vogl T. J., Kummel S., Hammerstingl R., Schellenbeck M., Schumacher G., Balzer T., Schwarz W., Muller P. K., Bechstein W. O., Mack M. G. et al: Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. // Radiology 1996, 200 (1):59-67

18. 18. Runge V. M.: Notes on "Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent". // AJR American journal of roentgenology 2008, 190 (6):1433-1434

19. 19. Vander Elst L., Laurent S., Bintoma H. M., Muller R. N.: Albumin-bound MRI contrast agents: the dilemma of the rotational correlation time. // MAGMA 2001, 12 (2-3):135-140

20. 20. Wendland M. F., Saeed M., Lauerma K., Derugin N., Mintorovitch J., Cavagna F. M., Higgins C. B.: Alterations in T1 of normal and reperfused infarcted myocardium after Gd-BOPTA versus GD-DTPA on inversion recovery EPI. // Magnetic resonance in medicine: official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 1997, 37 (3):448-456

21. 21. Fenchel M., Franow A., Martirosian P., Engels M., Kramer U., Stauder N. I., Helber U., Vogler H., Claussen C. D., Miller S.: 1 M Gd-chelate (gadobutrol) for multislice first-pass magnetic resonance myocardial perfusion imaging. // The British journal of radiology 2007, 80 (959):884-892

22. 22. Bluemke D. A., Sahani D., Amendola M., Balzer T., Breuer J., Brown J. J., Casalino D. D., Davis P. L., Francis I. R., Krinsky G. et al: Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. // Radiology 2005, 237 (1):89-98

23. 23. Noebauer-Huhmann I. M., Szomolanyi P., Juras V., Kraff O., Ladd M. E., Trattnig S.: Gadolinium-based magnetic resonance contrast agents at 7 Tesla: in vitro T1 relaxivities in human blood plasma. // Invest Radiol 2010, 45 (9):554-558

24. 24. de Haen C., Anelli P. L., Lorusso V., Morisetti A., Maggioni F., Zheng J., Uggeri F., Cavagna F. M.: Gadocoletic acid trisodium salt (b22956/1): a new blood pool magnetic resonance contrast agent with application in coronary angiography. // Invest Radiol 2006, 41 (3):279-291

25. 25. Atar E.: Gadolinium-based magnetic resonance imaging contrast agents in interventional radiology. // The Israel Medical Association journal: IMAJ 2004, 6 (7):412-414

26. 26. Carlos R. C., Hussain H. K., Song J. H., Francis I. R.: Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid as an intrabiliary contrast agent: preliminary assessment. // AJR American journal of roentgenology 2002, 179 (1):87-92

27. 27. Giesel F. L., von Tengg-Kobligk H., Wilkinson I. D., Siegler P., von der Lieth C. W., Frank M., Lodemann K. P., Essig M.: Influence of human serum albumin on longitudinal and transverse relaxation rates (r1 and r2) of magnetic resonance contrast agents. // Invest Radiol 2006, 41 (3):222-228

28. 28. Kirchin M. A., Runge V. M.: Contrast agents for magnetic resonance imaging: safety update. // Topics in magnetic resonance imaging: TMRI 2003, 14 (5):426-435

29. 29. Peldschus K., Hamdorf M., Robert P., Port M., Graessner J., Adam G., Herborn C. U.: Contrast-enhanced magnetic resonance angiography: evaluation of the high relaxivity low diffusible gadolinium-based contrast agent P846 in comparison with gadoterate meglumine in rabbits at 1.5 Tesla and 3.0 Tesla. // Invest Radiol 2008, 43 (12):837-842

30. 30. van Montfoort J. E., Stieger B., Meijer D. K., Weinmann H. J., Meier P. J., Fattinger K. E.: Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. // The Journal of pharmacology and experimental therapeutics 1999, 290 (1):153-157

31. 31. Rohrer M., Bauer H., Mintorovitch J., Requardt M., Weinmann H. J.: Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. // Invest Radiol 2005, 40 (11):715-724

32. 32. Heidemann R. M., Ozsarlak O., Parizel P. M., Michiels J., Kiefer B., Jellus V., Muller M., Breuer F., Blaimer M., Griswold M. A. et al: A brief review of parallel magnetic resonance imaging. // European radiology 2003, 13 (10):2323-2337

33. 33. Faggioni L., Zampa V., Ortori S., Picano E., De Lucia R., Soldati E., Bongiorni M. G., Neri E., Bartolozzi C.: Time-resolved contrast-enhanced magnetic resonance angiography (CEMRA) of the left atrium-pulmonary veins complex with half dose of intravenous gadolinium-based contrast agent. Technical feasibility and comparison with a conventional CEMRA, full contrast dose protocol. // European journal of radiology 2012, 81 (2):250-256

34. 34. Шимановский Н. Л., Акопджанов А., Науменко В.: Наночастицы оксида железа физические и фармакологические свойства. Москва: GmbH&Co; 2012,

35. 35. Fink C., Puderbach M., Ley S., Plathow C., Bock M., Zuna I., Kauczor H. U.: Contrast-enhanced three-dimensional pulmonary perfusion magnetic resonance imaging: intraindividual comparison of 1.0 M gadobutrol and 0.5 M Gd-DTPA at three dose levels. // Invest Radiol 2004, 39 (3):143-148

36. 36. Sugio S., Kashima A., Mochizuki S., Noda M., Kobayashi K.: Crystal structure of human serum albumin at 2.5 A resolution. // Protein engineering 1999, 12 (6):439-446

37. 37. Ruehm S. G., Nanz D., Baumann A., Schmid M., Debatin J. F.: 3D contrast-enhanced MR angiography of the run-off vessels: value of image subtraction. // Journal of magnetic resonance imaging: JMRI 2001, 13 (3):402-411

38. 38. Bellin M. F., Vasile M., Morel-Precetti S.: Currently used non-specific extracellular MR contrast media. // European radiology 2003, 13 (12):2688-2698

39. 39. de Haen C., Calabi L., La Ferla R.: The problematic determination of proton magnetic relaxation rates of protein-containing solutions. // Academic radiology 2002, 9 Suppl 1:S2-4

40. 40. PubChem: Gadoxetic acid. http://pubchem.ncbi.nlm.nih.gov/image/structurefly.cgi?cid=450096&width=400&height=400 (дата обращения 23.05.2012).

41. 41. Chanyaputhipong J., Low S. C., Chow P. K.: Gadoxetate Acid-Enhanced MR Imaging for HCC: A Review for Clinicians. // International journal of hepatology 2011, 2011:489342

42. 42. MAGNETOM Verio 3T. http://www.medical.siemens.com/webapp/wcs/stores/servlet/ImageViewer?imageId=698293&current=0&imageTable=1&langId=-11&catalogId=-11&storeId=10001&maxWidth=814&maxHeight=667 (дата обращения 22.05.2012).

43. 43. software S. i.: Syngo via. Syngo EVOLVE. http://www.medical.siemens.com/webapp/wcs/stores/servlet/LandingPage?storeId=10001&langId=-11&catalogId=-11&catTree=100010,1008631,1029622,1029618,200650&pageId=125332&_nc_showLayer=1 (Дата обращения:22.05.2012).

44. 44. Пискунова Л. П.: Клиническая лабораторная диагностика. Национальное руководство. vol. 1. Москва: ГЭОТАР-Медиа; 2012 г, 325

Литература по гадовисту

1. Tombach B, Heindel W: Value of 1.0 M gadolinium chelates: Review of preclinical and clinical data on gadobutrol: Eur Radiol 12: 1550 – 1556 (2002).
2. Gadovist 1,0. The first 1molar contrast agent in MRI Schering AG, Germany (2004), p.48.
3. Benner T, Reimer P, Erb G, Schuierer G, Heiland S, Fischer C, Geens V, Sartor K, Forsting M: Cerebral MR perfusion imaging: First clinical application of a 1 molar gadolinium chelate (Gadovist® 1.0) in a double- blinded randomized dose finding study; JMRI 12: 371 – 380 (2000).
4. Tombach B, Benner T, Reimer P, Schuierer G, Fallenberg E, Geens V, Wels T, Sorensen A: Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 vs. 1.0 mol/L gadobutrol: Radiology 226: 880 – 888 (2003).
5. Chrysochou C, Power A, Shurrab AE, Husain S, Moser S, Lay J, Salama AD, Kalra PA. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Clin J Am Soc Nephrol. 2010; 5(3):484-489.
6. Prince M. R. Meaney J. F.M.Expanding role of MR angiographyin clinical practice Eur Radiol Suppl (2006) 16[Suppl 2]:B3–B8.

1. В.Н. Корниенко, И.Н. Пронин, Н.В. Арутюнов, С.В. Серков, Л.М. Фадеева, П.В. Родионов. Магнитно-резонансная томография с препаратом “Гадовист 1.0” в диагностике заболеваний головного и спинного мозга. МЕДИЦИНСКАЯ ВИЗУАЛИЗАЦИЯ № 2 2004, 122-129.
2. Anzalone N. et al. Detection of Cerebral Metastases on MRI: Intraindividual Comparison of Gadobutrol with Gadopentetate Dimeglumine. Acta Radiologica, 2009, Vol.50 (8), 933-940.
3. Giesel FL, Mehndiratta A, Risse F, et al. Intraindividual comparison between gadopentetate dimeglumine and gadobutrol for magnetic resonance perfusion in normal brain and intracranial tumors at 3 Tesla.// Acta Radiol. 2009 Jun; 50(5):521-30.
4. С.В. Елизарова, И.Е. Повереннова, С.К.Луценко. Применение 1,0 М контрастного средства (Гадовист 1,0) в обследовании больных c рассеянным склерозом на магнитно-резонансном томографе Signa 0,5 Tл. Медицинская визуализация 1/2006 с. 140-144.
5. Gadovist 1.0. The power of Contrast. Monograph. Bayer Schering Pharma AG., Berlin, 2007, p.72.
6. Uysal E, Erturk S M, Yildirim H, Seleker F, Basak M. Sensitivity of immediate and delayed gadolinium-enhanced MRI after injection of 0.5 M and 1.0 M gadolinium chelates for detecting multiple sclerosis lesions//American Journal of Roentgenology, 2007, 188, 3: 697-702
7. Schaefer FKW et al., A multicenter, site-independent, blinded study to compare the diagnostic accuracy of contrast-enhanced magnetic resonance angiography using 1.0 M gadobutrol (GadovistTM) to intraarterial digital subtraction angiography in body arteries, Eur J Radiol. 2007 Feb; 61(2):315-23.
8. Herborn C. Peripheral contrast-enhanced 3D MRA with 1.0 M gadobutrol. Europ.Radiol., 2004, 14, suppl.5, M23-M25
9. Attenberger UI, Runge VM, Jackson CB, et al/. Comparative evaluation of lesion enhancement using 1 M gadobutrol vs. 2 conventional gadolinium chelates, all at a dose of 0.1 mmol/kg, in a rat brain tumor model at 3 T. Invest Radiol. 2009 May;44(5):251-6.
10. Hammerstingl R, Adam G, Ayuso JR, et al Comparison of 1.0 M Gadobutrol and 0.5 M Gadopentetate Dimeglumine-Enhanced Magnetic Resonance Imaging in Five Hundred Seventy-Two Patients With Known or Suspected Liver Lesions: Results of a Multicenter, Double-Blind, Interindividual, Randomized Clinical Phase-III Trial. Invest Radiol. March 2009 - Volume 44 - Issue 3 - pp 168-176
11. Tombach B, Bohndorf K, Brodtrager W, et al.Comparison of 1.0 M gadobutrol and 0.5 M gadopentate dimeglumine-enhanced MRI in 471 patients with known or suspected renal lesions: results of a multicenter, single-blind, interindividual, randomized clinical phase III trial. Eur Radiol. 2008 Nov;18(11):2610-9.
12. T. Engelhorn, A. Doerfler High-molar contrast agents for CNS application, IMAGING DECISIONS # 4/2007, 26-32 p.
13. Voth M, Michaely HJ, Schwenke C, Vos B, Pietsch H.Contrast-enhanced magnetic resonance angiography (MRA): evaluation of three different contrast agents at two different doses (0.05 and 0.1 mmol/kg) in pigs at 1.5 Tesla.Eur Radiol. 2011 Feb;21(2):337-44.
14. Voth M. Haneder S, Huck K, Gutfleisch A, Schönberg SO, Michaely HJ. Peripheral magnetic resonance angiography with continuous table movement in combination with high spatial and temporal resolution time-resolved MRA With a total single dose (0.1 mmol/kg) of gadobutrol at 3.0 T. Invest Radiol 2009, Vol 44, 9, 627-633
15. Forsting М., Palkowitsch Р. Eur J Radiol 2009, June 30 2007 Feb;61(2):315-23
16. Bernd Tombach, Christoph Bremer, “Using Highly Concentrated Gadobutrol as an MR Contrast Agent in Patients Also Requiring Hemodialysis: Safety and Dialysability” AJR:178, January 2002, 105-109.
17. E.S. Kim, J.H. Chang, H.S. Choi, J. Kim and S.-K. Lee Diagnostic Yield of Double-Dose Gadobutrol in the Detection of Brain Metastasis: Intraindividual Comparison with Double-Dose Gadopentetate Dimeglumine. American Journal of Neuroradiology, 2010, 31:1055-1058.
18. Лучевая диагностика рассеянного склероза. / Трофимова Т.Н., Тотолян Н.А., Ананьева Н.И., Халиков А.Д., Пахомов А.В. – С.-Петербург «Элби-СПб». 2010. – 128с.
19. Katakami N. et al. Magnetic Resonance Evaluation of Brain Metastases from Systemic Malignances With Two Doses of Gadobutrol 1.0 M Compared With Gadoteridol. Investigative Radiology, 2011, in press.
20. Фармакоэкономическая оценка применения одномолярного гадолиний-содержащего магнитнорезонансного контрастного средства по сравнению с полумолярными препаратами для диагностики заболеваний ЦНС. // Готовится к публикации
21. Voth M, Rosenberg M, Breuer J. Safety of gadobutrol, a new generation of contrast agents: experience from clinical trials and postmarketing surveillance//Invest Radiol. 2011 Nov;46(11):663-671.
22. Katakami N, Inaba Y, Sugata S, Tsurusaki M, Itoh T, Machida T, Tanaka H, Nakayama T, Morikawa T, Breuer J, Aitoku Y.Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.// Invest Radiol. 2011 Jul;46(7):411-418.

1. Hahn G, Sorge I, Gruhn B, Glutig K, Hirsch W, Bhargava R, Furtner J, Born M, Schröder C, Ahlström H, Kaiser S, Moritz JD, Kunze CW, Shroff M, Stokland E, Trnkova ZJ, Schultze-Mosgau M, Reif S, Bacher-Stier C, Mentzel HJ.Pharmacokinetics and safety of gadobutrol-enhanced magnetic resonance imaging in pediatric patients.// Invest Radiol. 2009 Dec;44(12):776-783.

Дата добавления: 2015-07-25